Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Euro-Med Laboratories Philippines EV-to-EBITDA?
Euro-Med Laboratories PhilippinesPHS:EURO 80 EV-to-EBITDA is 5.07 as of Aug. 13, 2026, which is 35% below its 10-year median of 7.75. GuruFocus rates PHS:EURO with a GF Score™ of 80/100 and a GF Value™ of ₱1.04 (Fairly Valued). The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 86.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Euro-Med Laboratories Philippines's enterprise value is ₱6,726 Mil.
Euro-Med Laboratories Philippines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₱1,326 Mil. Therefore, Euro-Med Laboratories Philippines's EV-to-EBITDA for today is 5.07.
The historical rank and industry rank for Euro-Med Laboratories Philippines's EV-to-EBITDA or its related term are showing as below:
PHS:EURO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.89 Med: 7.75 Max: 44.73
Current: 5.07
During the past 13 years, the highest EV-to-EBITDA of Euro-Med Laboratories Philippines was 44.73. The lowest was 4.89. And the median was 7.75.
PHS:EURO's EV-to-EBITDA is ranked better than 86.24% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs PHS:EURO: 5.07
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Euro-Med Laboratories Philippines's PE Ratio (TTM) for today is calculated as:
Euro-Med Laboratories Philippines's share price for today is ₱1.04.
Euro-Med Laboratories Philippines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's EV-to-EBITDA falls into.
Euro-Med Laboratories Philippines's current Enterprise Value is ₱6,726 Mil.
Euro-Med Laboratories Philippines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱1,326 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a EV-to-EBITDA of 5.07 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Euro-Med Laboratories Philippines. This is 35% below median its historical median of 7.75. Over the past decade, Euro-Med Laboratories Philippines' EV-to-EBITDA has ranged from 4.89 to 44.73. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 734 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is Euro-Med Laboratories Philippines' EV-to-EBITDA too high?
Euro-Med Laboratories Philippines' current EV-to-EBITDA of 5.07 is 35% below median its 10-year median of 7.75. Over the past 10 years, this metric has ranged from a low of 4.89 to a high of 44.73. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Euro-Med Laboratories Philippines' value of 5.07 is 62% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 734 companies for EV-to-EBITDA. This places Euro-Med Laboratories Philippines in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.36. Euro-Med Laboratories Philippines' value of 5.07 is 62% below this benchmark. Historically, Euro-Med Laboratories Philippines' own EV-to-EBITDA has ranged from 4.89 to 44.73 over the past decade. While the company's 10-year median is 7.75 vs. the industry median of 13.36, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current EV-to-EBITDA of 5.07 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Euro-Med Laboratories Philippines. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current EV-to-EBITDA is 5.07, which is 35% below median its own 10-year median of 7.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.04, compared to a current price of ₱1.04 — trading right at its estimated fair value. The current EV-to-EBITDA is 5.07, which is 35% below median its 10-year median of 7.75 and 62% below the Drug Manufacturers industry median of 13.36. Euro-Med Laboratories Philippines' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current EV-to-EBITDA is 5.07 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be undervalued.
The current stock price of ₱1.04 is trading 0% below its estimated GF Value™ of ₱1.04.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
EV-to-EBITDA: 5.07 (35% below median its 10-year median of 7.75)
GF Value™: ₱1.04 vs. price of ₱1.04 (0% below fair value)
Industry Position: 62% below the Drug Manufacturers median (#101 of 734)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
80GF Score
Get the complete analysis for PHS:EURO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
